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M A J O R A R T I C L E
Epidemiology and Outcomes of Candidemia in 2019
Patients: Data from the Prospective Antifungal
Therapy Alliance Registry
David L. Horn,1 Dionissios Neofytos,1,2 Elias J. Anaissie,3 Jay A. Fishman,4 William J. Steinbach,5 Ali J. Olyaei,6
Kieren A. Marr,2 Michael A. Pfaller,7 Chi-Hsing Chang,8 and Karen M. Webster9
1Thomas Jefferson University Hospital, Philadelphia, Pennsylvania; 2Johns Hopkins University School of Medicine, Baltimore, Maryland; 3University
of Arkansas for Medical Sciences, Little Rock; 4Massachusetts General Hospital, Boston; 5Duke University Medical Center, Durham, North
Carolina; 6Oregon Health Sciences University, Portland; 7University of Iowa Health Care, Iowa City; and 8Info-Spectrum, Markham, and 9EBM
Consulting, Mississauga, Ontario, Canada
Background. Candidemia remains a major cause of morbidity and mortality in the health care setting, and
the epidemiology of Candida infection is changing.
Methods. Clinical data from patients with candidemia were extracted from the Prospective Antifungal Therapy
(PATH) Alliance database, a comprehensive registry that collects information regarding invasive fungal infections.
A total of 2019 patients, enrolled from 1 July 2004 through 5 March 2008, were identified. Data regarding the
candidemia episode were analyzed, including the specific fungal species and patient survival at 12 weeks after
diagnosis.
Results. The incidence of candidemia caused by non–Candida albicans Candida species (54.4%) was higher
than the incidence of candidemia caused by C. albicans (45.6%). The overall, crude 12-week mortality rate was
35.2%. Patients with Candida parapsilosis candidemia had the lowest mortality rate (23.7%; ) and wereP ! .001
less likely to be neutropenic (5.1%; ) and to receive corticosteroids (33.5%; ) or other immuno-P ! .001 P ! .001
suppressive drugs (7.9%; ), compared with patients infected with other Candida species. Candida kruseiPp .002
candidemia was most commonly associated with prior use of antifungal agents (70.6%; ), hematologicP ! .001
malignancy (52.9%; ) or stem cell transplantation (17.7%; ), neutropenia (45.1%; ), andP ! .001 P ! .001 P ! .001
corticosteroid treatment (60.8%; ). Patients with C. krusei candidemia had the highest crude 12-weekP ! .001
mortality in this series (52.9%; ). Fluconazole was the most commonly administered antimicrobial, followedP ! .001
by the echinocandins, and amphotericin B products were infrequently administered.
Conclusions. The epidemiology and choice of therapy for candidemia are rapidly changing. Additional study
is warranted to differentiate host factors and differences in virulence among Candida species and to determine
the best therapeutic regimen.
Candidemia is a major cause of morbidity and mortality
in the health care setting. However, the incidence of
candidemia is increasing with greater complexity of sur-
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gical procedures, patient populations at higher risk of
infection, and changes in patient demographic char-
acteristics. Prolongation of survival among critically ill
patients, especially in the intensive care unit setting, has
lead to increased use of invasive procedures, intrave-
nous catheters, and intravenous hyperalimentation, all
of which are risk factors for candidemia [1–3]. Recently,
the introduction of additional antifungal agents has led
to new strategies for empirical and prophylactic ther-
apies. An increasing number of candidial infections are
now caused by non–Candida albicans Candida species
[4–10].
Candidemia remains associated with high crude and
attributable mortality rates and with increased costs of
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Figure 1. Distribution of isolated Candida species. CALB, Candida albicans; CDUB, Candida dubliniensis; CGLB, Candida glabrata; CGUI, Candida
guillermondii; CKRU, Candida krusei; CLUS, Candida lusitaniae; CPAR, Candida parapsilosis; CTRO, Candida tropicalis.
care and duration of hospitalization. Attributable mortality has
been reported to range from 5% to 71%, and crude mortality
rates have been reported to be as high as 81% [11–23]. In-
appropriate therapy or delays in initiation of therapy have also
been linked to increased mortality [24, 25]. This study was
performed to evaluate contemporary epidemiology and out-
comes of candidemia in multiple North American centers.
METHODS
The patient population for this study was extracted from the
Prospective Antifungal Therapy (PATH) Alliance database. The
PATH Alliance is a comprehensive multicenter, prospective,
observational registry that collects detailed clinical data on pa-
tients with invasive fungal infections (IFIs), with special em-
phasis on fungal epidemiology, diagnosis, treatment, and as-
sociated patient outcomes [26, 27].
This study is based on data for the 2019 patients (pediatric
and adult) enrolled from 1 July 2004 through 5 March 2008
from 23 North American centers who received a diagnosis of
proven candidemia. Detailed information with regard to can-
didemia episodes were analyzed, including underlying patient
characteristics, the specific fungal pathogen and species, anti-
fungal therapy, and survival.
A diagnosis of candidemia was made on the basis of 1
blood cultures growing Candida species and the presence of
relevant clinical signs and symptoms, as enumerated in the
guidelines of the European Organization for Research and
Treatment of Cancer/Invasive Fungal Infections Cooperative
Group and the National Institute of Allergy and Infectious
Diseases Mycoses Study Group [28]. Only the first episode of
candidemia was reported for patients with recurrent or sub-
sequent episodes of infection. Patients whose cultures grew 11
documented species of Candida were excluded from analysis.
Some of these patients are described elsewhere [26].
Fisher’s exact test or x2 test, as appropriate, was used for
testing associations between categorical patient characteristics
and Candida species. Analysis of variance was used for testing
the difference in mean values across Candida species. Survival
distribution function was estimated using the Kaplan-Meier
product-limit method; nonparametric (log-rank and Wilcoxon)
tests were used to compare the survival functions among the
different Candida species. Patients were considered to be lost
to follow-up if they were discharged home or transferred to
another institution prior to the 12-week assessment date and
no additional information was available.
RESULTS
Among the 4010 patients with completed case reports of IFIs,
2019 patients (50.3%) with proven candidemia caused by a
single species were identified by the PATH Alliance registry. The
distribution of isolated Candida species is shown in figure 1.
C. albicans was commonly identified (45.6%); however, collec-
tively, non–C. albicans Candida species were more frequently
isolated from blood cultures (54.4%). The majority of the other
species identified included Candida glabrata (26.0%), Candida
parapsilosis (15.7%), Candida tropicalis (8.1%), and Candida
krusei (2.5%).
The mean age of patients was 53.5 years (range, 0–96.4 years),
and 53.7% were male. Most of the patients were white (62.6%),
followed by black (21.7%). Of note, 43.0% of the patients had
received antifungal agents as prophylaxis or empirical therapy
within 30 days prior to their diagnosis of candidemia. A com-
parison of patient characteristics across isolated Candida species
is presented in table 1. Statistically significant differences were
found in the distribution of Candida species with regard to age
( ), sex ( ), prior antifungal therapy ( ),P ! .001 Pp .002 P ! .001
presence of hematologic malignancy ( ), hematopoieticP ! .001
stem cell ( ) or solid organ transplantation ( ),P ! .001 Pp .009
neonatal intensive care unit stay ( ), surgery (Pp .009 Pp
), requirement of total parenteral nutrition ( ), me-.04 Pp .04
chanical ventilation ( ), use of central catheters (pe-Pp .04
ripherally inserted, ; tunneled, ; nontunneled,Pp .05 Pp .01
), presence of neutropenia ( ), use of cortico-Pp .03 P ! .001
steroids ( ) or other immunosuppressive agents (P ! .001 Pp
), and presence of concomitant bacterial infections (.002 Pp
)..04
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Table 1. Patient baseline characteristics, by isolated Candida species.
Characteristic
Candida species
P
All
(n p 2019)
Candida albicans
(n p 921)
Candida glabrata
(n p 525)
Candida parapsilosis
(n p 316)
Candida tropicalis
(n p 163)
Candida krusei
(n p 51)
Othera
(n p 43)
Age, mean years (range) 53.5 (0–96.4) 51.9 (0–96.4) 58.7 (0.8–95.8) 50.1 (0–95.0) 53.8 (1.3–87.6) 49.7 (6.1–84.9) 50.9 (0–79.1) !.001
Male sex 1084 (53.7) 502 (54.5) 251 (47.8) 173 (54.8) 105 (64.4) 24 (47.1) 29 (67.0) .002
Ethnicity
White 1264 (62.6) 571 (62.0) 342 (65.1) 193 (61.1) 93 (57.1) 32 (62.8) 33 (76.7) .17
Black 439 (21.7) 200 (21.7) 115 (21.9) 69 (21.8) 41 (25.2) 6 (11.8) 8 (18.6) .50
Hispanic 65 (3.2) 25 (2.7) 15 (2.9) 14 (4.4) 8 (4.9) 3 (5.9) 0 (0) .26
Asian 24 (1.2) 10 (1.1) 5 (1.0) 4 (1.3) 3 (1.8) 1 (2.0) 1 (2.3) .89
Other or unknown 227 (11.2) 115 (12.5) 48 (9.1) 36 (11.4) 18 (11.0) 9 (17.7) 1 (2.3) .10
Prior antifungal therapy 869 (43.0) 358 (38.9) 272 (51.8) 119 (37.7) 68 (41.7) 36 (70.6) 16 (37.2) !.001
Patient categoryb
General medicine 1339 (66.3) 620 (67.3) 356 (67.8) 210 (66.5) 100 (61.4) 26 (51.0) 27 (62.8) .14
Hematologic malignancy 197 (9.8) 54 (5.9) 51 (9.7) 23 (7.3) 34 (20.9) 27 (52.9) 8 (18.6) !.001
Stem cell transplantation 58 (2.9) 13 (1.4) 19 (3.6) 9 (2.9) 5 (3.1) 9 (17.7) 3 (7.0) !.001
HIV infection and/or AIDS 41 (2.0) 18 (2.0) 12 (2.3) 4 (1.3) 3 (1.8) 2 (3.9) 2 (4.7) .61
Neonatal ICU stay 26 (1.3) 18 (2.0) 0 (0) 7 (2.2) 0 (0) 0 (0) 1 (2.3) .009
Solid organ transplantation 166 (8.2) 65 (7.1) 64 (12.2) 20 (6.3) 10 (6.1) 3 (5.9) 4 (9.3) .009
Solid tumor 351 (17.4) 167 (18.1) 94 (17.9) 45 (14.2) 26 (16.0) 9 (17.7) 10 (23.3) .56
Surgical (nontransplantation) 662 (32.8) 317 (34.4) 159 (30.3) 117 (37.0) 48 (29.5) 9 (17.7) 12 (27.9) .04
Organ functionb
Dialysis dependent 350 (17.3) 165 (17.9) 92 (17.5) 40 (12.7) 29 (17.8) 13 (25.5) 11 (25.6) .09
Diabetes mellitus 705 (34.9) 314 (34.1) 198 (37.7) 107 (33.9) 60 (36.8) 11 (21.6) 15 (34.9) .26
Total parenteral nutrition 751 (37.2) 349 (37.9) 197 (37.5) 131 (41.5) 50 (30.7) 11 (21.6) 13 (30.2) .04
Mechanical ventilation 722 (35.8) 364 (39.5) 175 (33.3) 101 (32.0) 56 (34.4) 14 (27.5) 12 (27.9) .04
Acute cardiac support 45 (2.2) 23 (2.5) 8 (1.5) 10 (3.2) 3 (1.8) 1 (2.0) 0 (0) .57
Ventricular shunt 34 (1.7) 17 (1.9) 7 (1.3) 9 (2.9) 1 (0.6) 0 (0) 0 (0) .32
Intravenous CC
Peripherally inserted CC 714 (35.4) 317 (34.4) 175 (33.3) 136 (43.0) 57 (35.0) 18 (35.3) 11 (25.6) .05
Tunneled CC 374 (18.5) 157 (17.0) 90 (17.1) 65 (20.6) 31 (19.0) 16 (31.4) 15 (34.9) .01
Nontunneled CC 653 (32.3) 313 (34.0) 184 (35.0) 77 (24.4) 49 (30.1) 16 (31.4) 14 (32.6) .03
Immune functionb
ANC !500 cells/mm3 148 (7.3) 47 (5.1) 30 (5.7) 16 (5.1) 24 (14.7) 23 (45.1) 8 (18.6) !.001
Corticosteroid therapy 828 (41.0) 369 (40.1) 225 (42.9) 106 (33.5) 71 (43.6) 31 (60.8) 26 (60.5) !.001
Immunosuppressive therapy 208 (10.3) 78 (8.5) 77 (14.7) 25 (7.9) 15 (9.2) 5 (9.8) 8 (18.6) .002
Concomitant infectionb
Cytomegalovirus 27 (1.3) 12 (1.3) 11 (2.1) 3 (1.0) 1 (0.6) 0 (0) 0 (0) .47
Bacterial infection 1080 (53.5) 492 (53.4) 282 (53.7) 176 (55.7) 93 (57.1) 16 (31.4) 21 (48.8) .04
NOTE. Data are no. (%) of patients, unless otherwise indicated. ANC, absolute neutrophil count; CC, central catheter; HIV, human immunodeficiency virus;
ICU, intensive care unit.
a Other species includes Candida lusitaniae (17 cases), Candida guillermondii (5), Candida dubliniensis (7), other (11), and unknown Candida species (3).
b Patient category, organ function, immunologic risk factors, and concomitant infections were not mutually exclusive (patients could have 11 characteristic
within a category).
The 316 patients with C. parapsilosis candidemia were least
likely to have risk factors including nontunneled central cath-
eter (24.4%), neutropenia (5.1%), or corticosteroid (33.5%) or
other immunosuppressive therapies (7.9%); they were most
likely to have had recent surgery (37.0%) or a peripherally
inserted central venous catheter (43.0%). C. krusei candidemia
(51 cases) was most commonly associated with younger age
(mean age, 49.7 years), female sex (52.9%), prior use of an-
tifungal agents (70.6%), hematologic malignancy (52.9%), stem
cell transplantation (17.7%), neutropenia (45.1%), or corti-
costeroid therapy (60.8%), and patients with C. krusei candi-
demia were less likely to require total parenteral nutrition
(21.6%) or mechanical ventilation (27.5%) or to have a con-
comitant bacterial infection (31.4%). The 525 patients with C.
glabrata candidemia were more likely to be older (mean age,
58.7 years) or to have undergone solid organ transplantation
(12.2%). Patients with C. albicans candidemia were the least
likely to have a hematologic malignancy (5.9%) and/or to have
undergone stem cell transplantation (1.4%). Although rarely
encountered, candidemia due to the rarest Candida species
(e.g., Candida dubliniensis and Candida lusitaniae) was more
likely to occur in male patients (67.0%) or in patients who had
tunneled central venous catheters (34.9%) or used immuno-
suppressive agents (18.6%).
Among the 2019 patients with candidemia, another 179 fun-
gal infections due to Candida species were identified at sites
other than blood, including the abdomen (95 cases [53.1%]),
lungs (17 [9.5%]), skin and soft tissue (14 [7.8%]), eyes (9
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Figure 2. Administered antifungal agents; some patients received 11 agent. AMB-LF, any lipid formulation of amphotericin B; AMB-d, amphotericin
B deoxycholate; CAS, caspofungin; FLU, fluconazole; MIC, micafungin; VOR, voriconazole.
Table 2. Antifungal therapy administered, by different Candida species.
Antifungal agent
Candida species, no. (%) of treated cases
All
(n p 2019)
Candida albicans
(n p 921)
Candida glabrata
(n p 525)
Candida parapsilosis
(n p 316)
Candida tropicalis
(n p 163)
Candida krusei
(n p 51)
Othera
(n p 43)
FLU 1366 (67.7) 714 (77.5) 273 (52.0) 233 (73.7) 98 (60.1) 16 (31.4) 32 (74.4)
VOR 136 (6.7) 45 (4.9) 44 (8.4) 21 (6.6) 12 (7.4) 10 (19.6) 4 (9.3)
AMB-D 44 (2.2) 23 (2.5) 6 (1.1) 9 (2.9) 2 (1.2) 2 (3.9) 2 (4.7)
ABCD 6 (0.3) 3 (0.3) 2 (0.4) 0 (0) 0 (0) 1 (2.0) 0 (0)
ABLC 86 (4.2) 33 (3.6) 12 (2.3) 25 (7.9) 10 (6.1) 4 (7.8) 2 (4.6)
L-AMB 110 (5.5) 38 (4.1) 24 (4.6) 27 (8.5) 7 (4.3) 9 (17.6) 5 (11.6)
LF-AMB 202 (10.0) 74 (8.0) 38 (7.2) 52 (16.4) 17 (10.4) 14 (27.4) 7 (16.3)
CAS 769 (38.1) 272 (29.5) 262 (49.9) 111 (35.1) 79 (48.5) 29 (56.9) 16 (37.2)
MIC 219 (10.9) 74 (8.0) 86 (16.4) 27 (8.5) 17 (10.4) 9 (17.7) 6 (14.0)
Blindb 34 (1.7) 18 (2.0) 7 (1.3) 4 (1.3) 2 (1.2) 3 (5.9) 0 (0)
Combination therapyc 68 (3.4) … … … … … …
NOTE. One patient received itraconazole or posaconazole, 3 patients received anidulafungin, and 6 patients received 5-fluorocytosine. ABCD, amphotericin
(AMB) colloid dispersion; ABLC, AMB lipid complex; AMB-D, AMB deoxycholate; FLU, fluconazole; L-AMB, liposomal AMB; LF-AMB, any lipid formulation of
AMB; CAS, caspofungin; MIC, micafungin; VOR, voriconazole.
a Other species includes Candida lusitaniae (17 cases), Candida guillermondii (5), Candida dubliniensis (7), other (11), and unknown Candida species (3).
b Blinded therapy as part of a clinical trial.
c Some patients received 1 antifungal agents as combination and/or sequential therapy.
[5.0%]), heart (7 [3.9%]), tracheobronchial tree (7 [3.9%]),
skeleton (3 [1.7%]), central nervous system (2 [1.1%]), and
other sites (25 [14.0%]). C. albicans was identified in 88 cases
(49.2%); non–C. albicans Candida species collectively were
more often isolated (91 cases [50.8%]). A small number of
patients had a concomitant IFI other than Candida infection,
including IFI due to Aspergillus species (11 patients), the Zy-
gomycetes (1), endemic fungi (1), other molds (1), and other
yeasts (5).
Administered antifungal agents are shown in figure 2. Flu-
conazole was most frequently used (67.7%), followed by cas-
pofungin (38.1%). Micafungin was the third most frequently
administered agent in this series (10.8%), followed by the lipid
formulations of amphotericin B (10.0%) and voriconazole
(6.7%). Amphotericin B deoxycholate was the agent that was
least frequently administered (2.2%). A small minority of pa-
tients had received sequential or combination therapies (3.4%).
Administered antifungal agents, stratified by Candida species,
are shown in table 2. Fluconazole was most commonly used
for cases of C. albicans candidemia (77.5%), and patients with
C. krusei candidemia were the most likely to receive therapy
with voriconazole (19.6%) or amphotericin B lipid formula-
tions (27.4%). Echinocandins (caspofungin and micafungin)
were used for the majority of patients with C. glabrata (66.3%)
and C. krusei (74.5%) candidemia. A total of 138 patients
(43.7%) with C. parapsilosis received an echinocandin.
Patient outcomes at 12 weeks and survival, stratified by Can-
dida species, are reported in table 3 and figure 3, respectively.
The overall, crude 12-week mortality rate was 35.2% (711 of
2019 patients died; 604 patients were lost to follow-up). C.
parapsilosis candidemia was associated with the lowest 12-week
mortality rate (23.7%). In contrast, patients with C. krusei can-
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Table 3. Twelve-week outcome, by isolated Candida species.
Status at
12 weeks after
diagnosis of IFI
Candida species, no. (%) of patients
All
(n p 2019)
Candida
albicans
(n p 921)
Candida
glabrata
(n p 525)
Candida
parapsilosis
(n p 316)
Candida
tropicalis
(n p 163)
Candida
krusei
(n p 51)
Othera
(n p 43)
Alive 704 (34.9) 306 (33.2) 189 (36.0) 124 (39.2) 50 (30.7) 17 (33.3) 18 (41.9)
Dead 711 (35.2) 328 (35.6) 200 (38.1) 75 (23.7) 67 (41.1) 27 (52.9) 14 (32.6)
Unknown 604 (29.9) 287 (31.2) 136 (25.9) 117 (37.0) 46 (28.2) 7 (13.7) 11 (25.6)
NOTE. , by log-rank test.P ! .001
a Other species included Candida lusitaniae (17 cases), Candida guillermondii (5), C. dubliniensis (7), other (11), and unknown
Candida species (3).
Figure 3. Survival among patients with candidemia at 12 weeks, by Candida species (Candida albicans, Candida glabrata, Candida krusei, Candida
parapsilosis, and Candida tropicalis).
didemia had the highest mortality rate (52.9%) in this cohort.
A statistically significant difference in the 12-week survival dis-
tributions by Candida species ( ) was found (figure 3).P ! .001
Survival patterns among patients with candidemia due to C.
albicans, C. glabrata, C. tropicalis, and other Candida species
were similar. A statistically significant difference in the 12-
week survival distributions ( ) was found based onP ! .001
age (83.2% for 0 to !19 years of age, 68.7% for 19–65 years
of age, and 52.7% for 165 years of age) (figure 4). When
analyzed by Candida species and age group, a similar pattern
was seen with C. albicans ( ), C. glabrata ( ), andP ! .001 P ! .002
C. parapsilosis ( ). No statistically significant differencesP ! .007
were observed with C. tropicalis, C. krusei, or other Candida
species. No statistically significant difference in the 12-week
survival distributions was found when analyzed by ethnicity
(data not shown).
DISCUSSION
A cohort of 2019 patients with candidemia was identified and
analyzed from the PATH Alliance registry, a prospective data-
base of IFIs at major North American medical centers. To our
knowledge, this is the largest cohort of patients with candi-
demia, with contemporary patients enrolled from July 2004
through March 2008. Other large series of patients with can-
didemia were from earlier periods, enrolled from 1991 through
2000 (1137 episodes of candidemia) [29] and from February
1995 through November 1997 (1447 adults and 144 children
with candidemia) [8]. We observed a predominance of non–
C. albicans Candida species (54.4%); C. albicans was the most
frequently isolated species (45.6%). We report an overall, 12-
week crude mortality rate of 35.2% among patients who ex-
perienced a single episode of candidemia, with the lowest mor-
tality observed among patients with C. parapsilosis candidemia
and the highest among patients with C. krusei candidemia.
Candidemia has been identified among the most common
etiologic agents of bloodstream infections. It ranked seventh in
a nationwide survey of 17 hospitals in Switzerland [29] and
fourth in the Surveillance and Control of Pathogens of Epi-
demiologic Importance (SCOPE) surveillance study of blood-
stream infections in hospitalized patients in the United States
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Figure 4. Survival among patients with candidemia at 12 weeks, by age group
[30]. C. albicans has traditionally been the predominant Can-
dida species isolated, followed by C. glabrata and other non–
C. albicans Candida species, in both pediatric and adult patient
populations [8, 29, 30]. In a worldwide surveillance program
(1997–2003) that included 134,715 consecutive clinical isolates
of Candida species from 127 medical centers in 39 countries,
a trend toward a decrease in C. albicans and an increase in C.
tropicalis and C. parapsilosis was noted [31]. In addition, species
distribution differences have been reported throughout the
world. For example, C. albicans and C. glabrata were most
frequently identified in series from Denmark and the United
States, although South America had lower rates of these species
[31].
In this study population from the PATH Alliance, non–C.
albicans Candida species were more frequently isolated than
was C. albicans (54.4% vs. 45.6%). Patients with C. glabrata
and C. krusei candidemia were the most likely to have received
prior antifungal therapy. This likely reflects, in part, selective
pressure because of the extensive use of prophylactic flucona-
zole in susceptible hosts [32, 33]. In addition, severe immu-
nosuppression or illness, prematurity, exposure to broad-spec-
trum antibiotics, and older age may contribute to the increased
incidence of candidemia caused by non–C. albicans Candida
species, especially C. glabrata, C. krusei, C. parapsilosis, and C.
tropicalis [34–41]. We observed an association between neu-
tropenia and the use of corticosteroids and C. krusei candi-
demia, consistent with the underlying medical conditions of
these patients, including hematologic malignancy and stem cell
transplantation, and the associated prior use of azole prophy-
laxis. Patients with C. krusei candidemia were younger and did
not generally have such additional risk factors as parenteral
nutrition, mechanical ventilation, and concomitant bacterial
infections. Older age and receipt of a solid organ transplant
were associated with C. glabrata candidemia. Our observations
suggest that the changing patient population and practices in-
volved in their care may contribute to the continual shift in
the epidemiology of Candida species.
In the present study, the azole antifungals were the most
frequently administered antifungal agents, followed by the
echinocandins. Combination therapy remains an uncommon
practice in the treatment of candidemia. Overall, amphotericin
B products were infrequently administered, especially ampho-
tericin B deoxycholate, which was used for !3% of patients.
The relatively recent introduction of echinocandins and azoles
will necessitate re-evaluation of clinical outcomes of therapy
for candidemia over time. The differences observed in the use
of antifungal agents based on the different Candida species may,
in part, be explained by the variations in their susceptibility
profiles (when available), empirical therapy based on existing
treatment guidelines [10], or differences in clinical practice,
including prophylactic programs, among the participating cen-
ters. As outlined in the recently revised guidelines for the treat-
ment of candidemia by the Infectious Diseases Society of Amer-
ica, treatment should be adjusted on the basis of the Candida
species isolated (42).
Retrospective cohort studies involving patients with candi-
demia and varying underlying diseases have revealed worldwide
crude and attributable mortality rates of 30%–81% and 5%–
71%, respectively [11–22]. In our series, patients with candi-
demia had a crude 12-week mortality rate of 35.2%. Survival
appears to be improved, compared with that in many older
studies. The identification of candidemia as one of the leading
causes of bloodstream infections [30] and greater knowledge
of major risk factors for candidemia [21] have likely led to
higher clinical suspicion, prompt initiation of diagnostic test-
ing, and pre-emptive or empirical treatment with new, effective,
and well-tolerated antifungal agents. In this series, the use of
nonculture diagnostic methods was rarely a factor in the ini-
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tiation of antifungal therapy (!1%). Thus, improved outcomes
could not be attributed to these diagnostic tools.
The highest and lowest crude mortality rates reported in the
SCOPE surveillance study [30] were for C. krusei and C. par-
apsilosis candidemia. Similarly, candidemia due to C. krusei was
associated with the highest mortality rate observed in this series
(52.9%). This can be explained, in part, by underlying immune
deficits in the patient populations most frequently affected by
these species, including patients with hematologic malignancies
and stem cell transplant recipients. Our findings suggest that
patients with C. parapsilosis candidemia have the lowest mor-
tality rate (23.7%); this finding is consistent with the results of
prior studies [20, 30, 43]. These patients were less likely to be
neutropenic or to be receiving corticosteroids and other im-
munosuppressive agents; this is consistent with the mechanism
by which C. parapsilosis causes infection, in association with
contaminated infusates and catheters. As was reported in a
separate analysis [44], we observed similar mortality rates for
C. albicans and C. glabrata candidemia in this study. Our find-
ings, based on a large number of patients, strongly suggest that
there may not be significant differences in survival associated
with infection due to the 2 most common Candida species.
Additional prospective or case-control studies are needed to
delineate differences between other specific Candida species.
Limitations of the present study include differences in clinical
practices across different centers, limited follow-up data, the
inability to clearly distinguish between prophylactic and em-
pirical therapy or sequential and concomitant antifungal ther-
apy, and the collection of data from only institutions in North
America. Despite these limitations, the data collected by the
PATH Alliance registry include a very large number of patients
with IFIs with a broad spectrum of underlying conditions. This
database will likely prove to be a significant asset in the un-
derstanding of IFIs, including candidemia [45]. Differences in
the outcomes and presentations of IFIs will be addressed by
the PATH Alliance with large cohort studies and case-control
studies to provide more information on optimal approaches to
candidemia and other IFIs.
PROSPECTIVE ANTIFUNGAL THERAPY (PATH)
ALLIANCE
Contributing sites. Thomas Jefferson University Hospital
(Philadelphia, PA), Massachusetts General Hospital (Boston),
University of Pittsburgh (Pittsburgh, PA), Duke University
Medical Center (Durham, NC), University of Arkansas for
Medical Sciences (Little Rock), University of Michigan Health
System (Ann Arbor), Washington Hospital Center (Washing-
ton, DC), Hamilton Health Sciences (Hamilton, Ontario, Can-
ada), University of Iowa Health Care (Iowa City), University
of Washington (Seattle), University of Wisconsin Medical
School (Madison), Oregon Health & Science University (Port-
land), University of Nebraska Medical Center (Omaha), Uni-
versity of Miami (Miami, FL), Mount Sinai School of Medicine
(New York, New York), University of Minnesota (Minneapolis),
University of Pennsylvania (Philadelphia), University of Ala-
bama at Birmingham (Birmingham), Emory University (At-
lanta, GA), Children’s Memorial Hospital (Chicago, IL), and
Hoˆpital Maisonneuve-Rosemont (Montreal, Quebec, Canada).
PATH Alliance investigators. E. Anaissie (University of Ar-
kansas), D. Andes (University of Wisconsin), M. Boeckh (Uni-
versity of Washington), J. Bubalo (Oregon Health & Science
University), L. Coopersmith (University of Arkansas), D. Diek-
ema (University of Iowa), J. Fishman (Massachusetts General
Hospital), A. Freifeld (University of Nebraska), S. Haider
(Hamilton Health Services), D. Horn (Thomas Jefferson Uni-
versity Hospital), S. Huprikar (Mount Sinai), S. Husain (Uni-
versity of Pittsburgh), J. Ito (City of Hope National Medical
Center), A. KatzSlenker (Thomas Jefferson University Hos-
pital), B. Katz (Children’s Memorial Hospital), C. Kauffman
(University of Michigan), M. Kletzel (Children’s Memorial
Hospital), Dimitrios Kontoyiannis (University of Texas), E. J.
Kwak (University of Pittsburgh), G. Lamaris (University of
Texas), M. Laverdiere (Hopital Maisonneuve Rosemont), M.
Leif (Mount Sinai), G. M. Lyon III (Emory University), K. Marr
(University of Washington), G. Mattiuzzi (University of Texas),
M. Morris (University of Miami), A. Olyaei (Oregon Health &
Science University), P. Pappas (University of Alabama), A. Peleg
(University of Pittsburgh), T. Perl (Johns Hopkins), M. Pfaller
(University of Iowa), C. Rotstein (Hamilton Health Services),
M. Schuster (University of Pennsylvania), S. Shoham (Wash-
ington Hospital Center), F. Silveira (University of Pittsburgh),
W. Steinbach (Duke University), L. Strasfeld (Oregon Health
& Science University), M. de Ungria (Children’s Memorial
Hospital), and J. A. Young (University of Minnesota).
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